You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 13, 2024

CLINICAL TRIALS PROFILE FOR CHLORDIAZEPOXIDE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CHLORDIAZEPOXIDE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00136617 ↗ Outpatient Treatment of Alcohol Withdrawal Syndrome Completed Hvidovre University Hospital Phase 3 2003-08-01 The purpose of this study is to compare a fixed-schedule therapy versus a symptom-triggered therapy for alcohol withdrawal syndrome in medical outpatients. Objectives: - Self-governance in monitoring AWS (alcohol withdrawal syndrome) symptoms and medication - Clinically controlled trial of two regimens for medical treatment of alcohol withdrawal syndrome - Outpatient treatment of alcohol withdrawal syndrome
NCT00202514 ↗ Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms Completed Abbott Phase 2/Phase 3 2004-09-01 The purpose of this study is to test the safety and effectiveness of an extended release form of a medication called divalproex sodium (Depakote ER) for the treatment of people with alcohol dependence who have mood and/or anxiety symptoms. This medication has helped reduce symptoms of acute alcohol withdrawal as well as stabilize mood symptoms in bipolar disorder and other mental health disorders. This study will test the hypothesis that divalproex sodium will help reduce mood and anxiety symptoms during early abstinence from alcohol and in turn reduce relapse and craving for alcohol.
NCT00202514 ↗ Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms Completed Seattle Institute for Biomedical and Clinical Research Phase 2/Phase 3 2004-09-01 The purpose of this study is to test the safety and effectiveness of an extended release form of a medication called divalproex sodium (Depakote ER) for the treatment of people with alcohol dependence who have mood and/or anxiety symptoms. This medication has helped reduce symptoms of acute alcohol withdrawal as well as stabilize mood symptoms in bipolar disorder and other mental health disorders. This study will test the hypothesis that divalproex sodium will help reduce mood and anxiety symptoms during early abstinence from alcohol and in turn reduce relapse and craving for alcohol.
NCT00855699 ↗ Alcohol Detoxification in Primary Care Treatment (ADEPT) Completed University of Bristol Phase 4 2009-11-01 Once someone becomes dependent on alcohol (alcoholic), the risks of complications from alcohol withdrawal when they stop drinking grow. These can include a life-threatening fit or delirium tremens (see things, become frightened). To prevent such complications, people take medication such as benzodiazepines (e.g., valium or librium) in reducing doses for about a week; this is called detoxification or 'detox.' In the UK effective alcohol treatment exists but little is known about what is the best detox medication. Alternative drugs to benzodiazepines appear to protect the brain from the toxicity of alcohol withdrawal and to reduce the likelihood of drinking again. This study will examine the feasibility of comparing medication regimens for alcohol detox for the first time in primary care. It will include a standard detox regimen (librium over 8 days) alone and together with a drug, acamprosate, that has been shown to reduce toxicity of alcohol withdrawal in preclinical models and is used after detox to help people remain sober. It will focus on the practicalities of doing such a study as well as assessing how people feel (withdrawal symptoms) and do (drinking during first month).
NCT01573052 ↗ Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal Completed VA Salt Lake City Health Care System Phase 4 2004-03-01 A randomized, double-blind controlled trial comparing treatment outcomes between chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects. The objective of this trial is to compare the safety and effectiveness of these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence, withdrawal severity scores, adverse events including ataxia, sedation, cognitive function and alcohol craving.
NCT02017197 ↗ Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil Completed Fundação de Amparo à Pesquisa do Estado de São Paulo Phase 4 2014-08-01 The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗ Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil Completed Federal University of São Paulo Phase 4 2014-08-01 The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CHLORDIAZEPOXIDE HYDROCHLORIDE

Condition Name

Condition Name for CHLORDIAZEPOXIDE HYDROCHLORIDE
Intervention Trials
Alcoholism 3
Alcohol Withdrawal 2
Addiction 1
Alcohol Related Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CHLORDIAZEPOXIDE HYDROCHLORIDE
Intervention Trials
Alcoholism 3
Substance Withdrawal Syndrome 2
Alcohol-Related Disorders 1
Diabetes Mellitus, Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CHLORDIAZEPOXIDE HYDROCHLORIDE

Trials by Country

Trials by Country for CHLORDIAZEPOXIDE HYDROCHLORIDE
Location Trials
United States 3
Taiwan 1
Denmark 1
Brazil 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CHLORDIAZEPOXIDE HYDROCHLORIDE
Location Trials
Minnesota 1
Utah 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CHLORDIAZEPOXIDE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for CHLORDIAZEPOXIDE HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2/Phase 3 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CHLORDIAZEPOXIDE HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 7
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CHLORDIAZEPOXIDE HYDROCHLORIDE

Sponsor Name

Sponsor Name for CHLORDIAZEPOXIDE HYDROCHLORIDE
Sponsor Trials
Chang Gung Memorial Hospital 1
Taipei City Hospital 1
Oregon Health and Science University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CHLORDIAZEPOXIDE HYDROCHLORIDE
Sponsor Trials
Other 9
Industry 1
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.